GCLC: A Tamoxifen-Based Drug for Cancer and Other Diseases (G2729)

Target Name: GCLC

NCBI ID: G2729

GCLC

GCLC: A Tamoxifen-Based Drug for Cancer and Other Diseases

GCLC (Glycophosphamide Combination) is a drug that is currently being studied for its potential as a treatment for various diseases, including cancer. It is a combination of two drugs, Glycophosphamide and P growth inhibitor, which can inhibit the growth and spread of cancer cells.

GCLC is a derivative of the drug tamoxifen, which is a hormone that is used to treat breast cancer. It works by inhibiting the activity of estrogen receptors, which are found on the surface of cancer cells. This can help to reduce the growth and spread of cancer cells.

In addition to its potential use in cancer treatment, GCLC is also being studied as a potential treatment for other diseases, including arthritis and osteoporosis. It is thought to work by inhibiting the activity of another protein called FAK, which is involved in cell signaling.

GCLC is also being studied for its potential use in treating other diseases, including heart disease and neurodegenerative disorders. In these cases, it is thought to work by inhibiting the activity of different proteins, including Src and TrkB, which are involved in cell signaling.

Overall, GCLC is a promising drug that is being studied for its potential as a treatment for a wide range of diseases. While more research is needed to fully understand its effects and potential, it is already being hailed as a potential game-changer in the field of cancer treatment.

Protein Name: Glutamate-cysteine Ligase Catalytic Subunit

Functions: Catalyzes the ATP-dependent ligation of L-glutamate and L-cysteine and participates in the first and rate-limiting step in glutathione biosynthesis

The "GCLC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GCLC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets